Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS Seeks Delay In Manufacturer Price Reporting Requirements

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacy trade group says average manufacturer prices should not be made public due to calculation inconsistencies.

You may also be interested in...



Louisiana Will Raise Generic Drug Dispensing Fees In 2007

Louisiana Governor signs legislation raising generic drug dispensing fees for pharmacists to counter lower reimbursement rates.

Louisiana Will Raise Generic Drug Dispensing Fees In 2007

Louisiana Governor signs legislation raising generic drug dispensing fees for pharmacists to counter lower reimbursement rates.

CMS Will Address Rebates And “Retail Class Of Trade” In AMP Regulation

The agency commented on an HHS Office of Inspector General report that found inconsistencies in average manufacturer price calculations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel